Pneumonia, ViralNCT04341766
Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19
An observational study of Pneumonia, Viral and COVID-19, run by Centre Hospitalier Intercommunal Creteil at 17 sites in France.
Trial summary
Clinical thoracic ultrasound plays an important role in the exploration, diagnosis and follow-up of thoracic pathologies. The COVID (Coronavirus Disease) epidemic is leading to a large influx of patients in the emergency department with respiratory disorders. Read more about this study
- Who is it for?
- Ages 18 to 105 years
- Conditions the study is for
- Pneumonia, Viral, COVID-19
- What is being tested?
- No special intervention
- How many people
- 106 participants
- Where
- 17 sitesFrance
- Study dates
- 31 Mar 2020to 30 Jun 2020
- How long will I take part?
- 6 Weeks
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 105 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient admitted to hospital with proven COVID-19 infection with respiratory signs and who need an hospitalization
Who may be able to join
- Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
Who cannot join
- Patient not agreeing to have his or her data collected for the study
- Unconscious patient
Trial locations and contacts
17 sites in 1 country.
17 sites in 1 country
France17 sites
CHU Amiens
Amiens, 80054
CH de la Côte Basque
Bayonne, 64109
CHU Ambroise Paré
Boulogne-Billancourt, 92104
CHU Caen
Caen, 14033
CHG de Chambery
Chambéry, 73000
Centre Hospitalier Intercommunal de Créteil
Créteil, 94000
CHU de Limoges
Limoges, 87000
APHM - Hopital Nord
Marseille, 13015
CHU de Nancy
Nancy, 54035
CHU Nîmes
Nîmes, 30029
CHR Orléans
Orléans, 45100
CHU Cochin
Paris, 75679
CHU Poitiers
Poitiers, 86021
CHU Rouen
Rouen, 76038
CH Saint-Quentin
Saint-Quentin, 02321
CHU Larrey - Toulouse
Toulouse, 31059
CHU de Tours
Tours, 37000
About this study
Official title: Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19
Clinical thoracic ultrasound plays an important role in the exploration, diagnosis and follow-up of thoracic pathologies.
The COVID (Coronavirus Disease) epidemic is leading to a large influx of patients in the emergency department with respiratory disorders. The rapid diagnosis of respiratory disorders in infected patients is important for further management.
Chest ultrasound has already demonstrated its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.
However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.
Read the detailed description
Chest ultrasound has already shown its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.
However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.
Peng reported data from 20 patients and compared them to chest CT. The abnormalities are a thickening of the pleuropneumonia line, an interstitial syndrome with B lines, corresponding to frosted glass opacities, confluent B lines (snowstorm appearance) corresponding to interstitial infiltrate, sub-pleural alveolar opacities corresponding to sub-pleural condensations, more frank alveolar images corresponding to alveolar opacities. A multifocal aspect was associated with involvement of more than 2 lobes. However, the frequency of these abnormalities as well as the sensitivity of the echo are not detailed in this article.
Another Italian article describes a clinical case of COVID-19 pneumonia with sub-pleural involvement and irregularity of the pleuro-pulmonary line.
Clinical thoracic ultrasound has a major potential interest during the COVID epidemic: available at the patient's bedside, avoiding the need to move around, feasible for the physician during his visit, easy to clean especially if ultraportable devices are used, fast and not exposing the staff any more than the usual clinical examination.
In order to determine whether this technique is useful in the management of infected patients or patients suspected of COVID-19 infection with respiratory signs, we propose a descriptive prospective study evaluating the ultrasound semiology of COVID-19 pneumonia and the interest of ultrasound in the evolutionary follow-up of these patients.
- Conditions
- Pneumonia, Viral, COVID-19
- Being tested
- No special intervention
- Medical subject headings
- Pneumonia, Viral, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No special interventionOther
No special intervention : Ultrasound data will be collected
| Study group | Role | What they receive |
|---|---|---|
| Patient hospitalised with COVID-19 infection | Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan Receives: Other: No special intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Characteristics of pulmonary ultrasound for Covid-19 patients
description of ultrasound abnormalities for Covid-19 patients
Measured: Day one
Secondary outcomes (5)
Characteristics of pulmonary ultrasound for Covid-19 patients
description of ultrasound abnormalities for Covid-19 patients
Measured: Day 3
Characteristics of pulmonary ultrasound for Covid-19 patients
description of ultrasound abnormalities for Covid-19 patients
Measured: Day 14
Charateristics of pulmonary CT-scan for Covid-19 patients
description of CT-scan abnormalities for Covid-19 patients
Measured: Day 1
Charateristics of pulmonary CT-scan for Covid-19 patients
description of CT-scan abnormalities for Covid-19 patients
Measured: Day 3
Charateristics of pulmonary CT-scan for Covid-19 patients
description of CT-scan abnormalities for Covid-19 patients
Measured: Day 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2020
- Study start31 Mar 2020
- Primary completion27 May 2020
- Study completion30 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pneumonia, ViralStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 106 participants (actual)
- Target duration
- 6 Weeks
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Intercommunal Creteil
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04341766
- Sponsor's protocol ID
- COVID-ECHO
- Status last verified
- Sep 2026
- First submitted
- 1 Apr 2020
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19
- ClinicalTrials.gov ID
- NCT04341766
- Acronym / sponsor ID
- COVID-ECHO
- Conditions
- Pneumonia, Viral, COVID-19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 106 participants (actual)
- Lead sponsor
- Centre Hospitalier Intercommunal CreteilUniversity, hospital or other
- Study start
- 31 Mar 2020 (actual)
- Primary completion
- 27 May 2020 (actual)
- Study completion
- 30 Jun 2020 (actual)
- First posted
- 10 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clinical thoracic ultrasound plays an important role in the exploration, diagnosis and follow-up of thoracic pathologies.
The COVID (Coronavirus Disease) epidemic is leading to a large influx of patients in the emergency department with respiratory disorders. The rapid diagnosis of respiratory disorders in infected patients is important for further management.
Chest ultrasound has already demonstrated its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.
However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.
Detailed description
Chest ultrasound has already shown its value in the diagnosis of pneumonia in the emergency department with superiority over chest X-ray.
However, there is little data on the thoracic ultrasound semiology of viral pneumonia in general and of COVID in particular.
Peng reported data from 20 patients and compared them to chest CT. The abnormalities are a thickening of the pleuropneumonia line, an interstitial syndrome with B lines, corresponding to frosted glass opacities, confluent B lines (snowstorm appearance) corresponding to interstitial infiltrate, sub-pleural alveolar opacities corresponding to sub-pleural condensations, more frank alveolar images corresponding to alveolar opacities. A multifocal aspect was associated with involvement of more than 2 lobes. However, the frequency of these abnormalities as well as the sensitivity of the echo are not detailed in this article.
Another Italian article describes a clinical case of COVID-19 pneumonia with sub-pleural involvement and irregularity of the pleuro-pulmonary line.
Clinical thoracic ultrasound has a major potential interest during the COVID epidemic: available at the patient's bedside, avoiding the need to move around, feasible for the physician during his visit, easy to clean especially if ultraportable devices are used, fast and not exposing the staff any more than the usual clinical examination.
In order to determine whether this technique is useful in the management of infected patients or patients suspected of COVID-19 infection with respiratory signs, we propose a descriptive prospective study evaluating the ultrasound semiology of COVID-19 pneumonia and the interest of ultrasound in the evolutionary follow-up of these patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Weeks
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient hospitalised with COVID-19 infection | – | Other: No special interventionPatients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan |
Who may qualify
- Ages
- 18 to 105 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient admitted to hospital with proven COVID-19 infection with respiratory signs and who need an hospitalization
Key inclusion criteria (1 listed)
- Patients admitted to hospital with proven COVID-19 infection with respiratory signs warranting a chest CT scan
Key exclusion criteria (2 listed)
- Patient not agreeing to have his or her data collected for the study
- Unconscious patient
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No special interventionNo special intervention : Ultrasound data will be collected | Other | Patient hospitalised with COVID-19 infection |
Primary outcome
Characteristics of pulmonary ultrasound for Covid-19 patients
Time frame: Day one
description of ultrasound abnormalities for Covid-19 patients
5 secondary outcomes
Characteristics of pulmonary ultrasound for Covid-19 patients
Time frame: Day 3
Characteristics of pulmonary ultrasound for Covid-19 patients
Time frame: Day 14
Charateristics of pulmonary CT-scan for Covid-19 patients
Time frame: Day 1
Charateristics of pulmonary CT-scan for Covid-19 patients
Time frame: Day 3
Charateristics of pulmonary CT-scan for Covid-19 patients
Time frame: Day 14
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Pneumonia, Viral
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
17 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumonia, Viral and COVID-19, run by Centre Hospitalier Intercommunal Creteil at 17 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 17 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Characteristics of pulmonary ultrasound for Covid-19 patients (time frame: Day one). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.